{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:06:58Z","timestamp":1794856018608,"version":"4.9.1"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cytogfr.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T18:41:00Z","timestamp":1722710460000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease"],"prefix":"10.1016","volume":"79","author":[{"given":"Zihan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2024.07.008_bib1","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082865","article-title":"The Use of JAK\/STAT inhibitors in chronic inflammatory disorders","volume":"12","author":"Caiazzo","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.07.008_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.07.008_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00011-021-01482-x","article-title":"Targeting JAK\/STAT signaling pathways in treatment of inflammatory bowel disease","volume":"70","author":"Wang","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.07.008_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus Kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231158235","article-title":"Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis","volume":"16","author":"Ernest-Suarez","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.07.008_bib8","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms AS EARLY AS Day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10341","key":"10.1016\/j.cytogfr.2024.07.008_bib9","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-023-00151-1","article-title":"JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions","volume":"4","author":"Sarapultsev","year":"2023","journal-title":"Mol. Biomed."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"13","key":"10.1016\/j.cytogfr.2024.07.008_bib12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/imt-2021-0096","article-title":"TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases","volume":"13","author":"Gonciarz","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib13","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"28","key":"10.1016\/j.cytogfr.2024.07.008_bib14","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.3748\/wjg.v26.i28.4055","article-title":"Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn\u2019s disease","volume":"26","author":"Cordes","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib15","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"675","key":"10.1016\/j.cytogfr.2024.07.008_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq4473","article-title":"Targeting cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.07.008_bib18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00348","article-title":"Transcriptional Regulators of T Helper 17 Cell Differentiation in Health and Autoimmune Diseases","volume":"11","author":"Capone","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.07.008_bib21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.4049\/jimmunol.1901112","article-title":"Disease Risk\u2013Associated Genetic Variants in STAT1 and STAT4 Function in a Complementary Manner to Increase Pattern-Recognition Receptor\u2013Induced Outcomes in Human Macrophages","volume":"205","author":"Hedl","year":"2020","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020187","article-title":"STAT3 Signalling via the IL-6ST\/gp130 Cytokine Receptor Promotes Epithelial Integrity and Intestinal Barrier Function during DSS-Induced Colitis","volume":"9","author":"Pang","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.cytogfr.2024.07.008_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350476","article-title":"S-palmitoylation regulates innate immune signaling pathways: molecular mechanisms and targeted therapies","volume":"53","author":"Cai","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/JOE-15-0098","article-title":"STAT4 contributes to adipose tissue inflammation and atherosclerosis","volume":"227","author":"Dobrian","year":"2015","journal-title":"J. Endocrinol."},{"issue":"14","key":"10.1016\/j.cytogfr.2024.07.008_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141326","article-title":"STAT4 is expressed in neutrophils and promotes antimicrobial immunity","volume":"6","author":"Mehrpouya-Bahrami","year":"2021","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.07.008_bib27","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.4049\/jimmunol.181.7.5062","article-title":"STAT4 Isoforms Differentially Regulate Th1 Cytokine Production and the Severity of Inflammatory Bowel Disease","volume":"181","author":"O'Malley","year":"2008","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embj.201899595","article-title":"STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation","volume":"38","author":"Zhang","year":"2019","journal-title":"EMBO J."},{"issue":"77","key":"10.1016\/j.cytogfr.2024.07.008_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl9467","article-title":"A central role for STAT5 in the transcriptional programing of T helper cell metabolism","volume":"7","author":"Villarino","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155392","article-title":"A centric view of JAK\/STAT5 in intestinal homeostasis, infection, and inflammation","volume":"139","author":"Surbek","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1039\/D3MD00451A","article-title":"Discovery of a dual-acting inhibitor of interleukin-1\u03b2 and STATs for the treatment of inflammatory bowel disease","volume":"15","author":"Cai","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib32","doi-asserted-by":"crossref","DOI":"10.4161\/jkst.23154","article-title":"Interleukin-2 and STAT5 in regulatory T cell development and function","volume":"2","author":"Mahmud","year":"2014","journal-title":"Jak. -Stat."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib33","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41385-019-0204-y","article-title":"Non-hematopoietic STAT6 induces epithelial tight junction dysfunction and promotes intestinal inflammation and tumorigenesis","volume":"12","author":"Lin","year":"2019","journal-title":"Mucosal Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.07.008_bib34","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: Not Just Another Kinase","volume":"21","author":"Agashe","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080898","article-title":"Pathogenic and Therapeutic Relevance of JAK\/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent","volume":"8","author":"Alunno","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.07.008_bib36","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/acs.jmedchem.2c01800","article-title":"Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"7422","key":"10.1016\/j.cytogfr.2024.07.008_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.07.008_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/mi.2017.104","article-title":"IFN-\u03b3-dependent epigenetic regulation instructs colitogenic monocyte\/macrophage lineage differentiation in vivo","volume":"11","author":"Nakanishi","year":"2018","journal-title":"Mucosal Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.07.008_bib39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/ibd\/izy265","article-title":"Genetic and Transcriptomic Variation Linked to Neutrophil Granulocyte\u2013Macrophage Colony-Stimulating Factor Signaling in Pediatric Crohn\u2019s Disease","volume":"25","author":"Denson","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"40","key":"10.1016\/j.cytogfr.2024.07.008_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306761120","article-title":"Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation","volume":"120","author":"Scarno","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"46","key":"10.1016\/j.cytogfr.2024.07.008_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav1080","article-title":"IL-23 and IL-2 activation of STAT5 is required for optimal IL-22 production in ILC3s during colitis","volume":"5","author":"Bauch\u00e9","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.644244","article-title":"An IFN-STAT Axis Augments Tissue Damage and Inflammation in a Mouse Model of Crohn's Disease","volume":"8","author":"Stolzer","year":"2021","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MOG.0b013e3283365279","article-title":"STAT3 and its activators in intestinal defense and mucosal homeostasis","volume":"26","author":"Hruz","year":"2010","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"36","key":"10.1016\/j.cytogfr.2024.07.008_bib44","doi-asserted-by":"crossref","first-page":"31263","DOI":"10.1074\/jbc.M111.238147","article-title":"Interleukin-6 (IL-6) Regulates Claudin-2 Expression and Tight Junction Permeability in Intestinal Epithelium","volume":"286","author":"Suzuki","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.07.008_bib45","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.4049\/jimmunol.1700152","article-title":"IL-22 Increases Permeability of Intestinal Epithelial Tight Junctions by Enhancing Claudin-2 Expression","volume":"199","author":"Wang","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib46","first-page":"1","article-title":"The Function and Role of the Th17\/Treg Cell Balance in Inflammatory Bowel Disease","volume":"2020","author":"Yan","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/emmm.201100192","article-title":"Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation","volume":"4","author":"Gilbert","year":"2012","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.07.008_bib48","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2013-305947","article-title":"IL-9 and its receptor are predominantly involved in the pathogenesis of UC","volume":"64","author":"Nalleweg","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054472","article-title":"Transcriptional inhibition of STAT1 functions in the nucleus alleviates Th1 and Th17 cell-mediated inflammatory diseases","volume":"13","author":"Park","year":"2022","journal-title":"Front. Immunol."},{"issue":"7829","key":"10.1016\/j.cytogfr.2024.07.008_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2799-2","article-title":"A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis","volume":"586","author":"Zhang","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cytogfr.2024.07.008_bib51","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-017-0755-8","article-title":"Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects","volume":"77","author":"Flamant","year":"2017","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.cytogfr.2024.07.008_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/nrgastro.2016.163","article-title":"A role for GATA3 in ulcerative colitis","volume":"13","author":"Ray","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.it.2014.04.002","article-title":"GATA3: a master of many trades in immune regulation","volume":"35","author":"Wan","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib54","article-title":"Lycium barbarum polysaccharide alleviates dextran sodium sulfate-induced inflammatory bowel disease by regulating M1\/M2 macrophage polarization via the STAT1 and STAT6 pathways","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02352-x","article-title":"Ketone body \u03b2-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway","volume":"20","author":"Huang","year":"2022","journal-title":"BMC Med."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082299","article-title":"Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment","volume":"19","author":"Kasembeli","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib57","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.cytogfr.2024.07.008_bib58","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohn'S. Colitis"},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib59","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/ibd\/izad007","article-title":"Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3","volume":"29","author":"Li","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.cytogfr.2024.07.008_bib61","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.07.008_bib62","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J. Crohn'S. Colitis"},{"issue":"21","key":"10.1016\/j.cytogfr.2024.07.008_bib63","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients \u2013 Analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"10290","key":"10.1016\/j.cytogfr.2024.07.008_bib65","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/art.42926","article-title":"Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"10349","key":"10.1016\/j.cytogfr.2024.07.008_bib68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"issue":"10349","key":"10.1016\/j.cytogfr.2024.07.008_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0140-6736(22)01384-8","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis","volume":"400","author":"Liew","year":"2022","journal-title":"Lancet"},{"issue":"10214","key":"10.1016\/j.cytogfr.2024.07.008_bib70","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib71","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: A Clinical Pharmacology Review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"10292","key":"10.1016\/j.cytogfr.2024.07.008_bib72","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib73","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.07.008_bib74","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","article-title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis","volume":"32","author":"Caso","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"14","key":"10.1016\/j.cytogfr.2024.07.008_bib75","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.cytogfr.2024.07.008_bib76","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7 Suppl 2","key":"10.1016\/j.cytogfr.2024.07.008_bib77","first-page":"6","article-title":"an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis: 12-Week Results From the Phase 2 LATTICE-UC Study","volume":"18","author":"Efficacy and Safety of Deucravacitinib","year":"2022","journal-title":"Gastroenterol. Hepatol. (N. Y)"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib78","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the Treatment of Psoriatic Disease","volume":"23","author":"L\u00e9","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib79","unstructured":"Pfizer, A. Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis., \u3008https:\/\/ichgcp.net\/clinical-trials-registry\/NCT042095562024\u3009 2020 (Accessed 15 May 2024)."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib80","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib81","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.07.008_bib82","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/apt.17185","article-title":"Review article: guide to tofacitinib dosing in patients with ulcerative colitis","volume":"56","author":"Irving","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.07.008_bib83","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis","volume":"118","author":"Ma","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib84","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izad242","article-title":"Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort","author":"Dalal","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.07.008_bib85","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience","volume":"14","author":"Honap","year":"2020","journal-title":"J. Crohn'S. Colitis"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.07.008_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103504","article-title":"Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study","volume":"23","author":"Solitano","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib88","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1007\/s10620-022-07444-5","article-title":"Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn\u2019s Disease","volume":"67","author":"Lee","year":"2022","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib89","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ibd\/izab176","article-title":"Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn\u2019s Disease","volume":"28","author":"Lee","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106847","article-title":"Jr, Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States","volume":"194","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib91","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CEG.S375969","article-title":"Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials","volume":"Volume 16","author":"AlAmeel","year":"2023","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib92","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","article-title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","volume":"64","author":"Pemmaraju","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.07.008_bib93","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/s41385-018-0051-2","article-title":"The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis","volume":"11","author":"Overstreet","year":"2018","journal-title":"Mucosal Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/toxsci\/kfac002","article-title":"Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species","volume":"186","author":"Hardwick","year":"2022","journal-title":"Toxicol. Sci."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.07.008_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105467","article-title":"A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis","volume":"299","author":"Bu","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.07.008_bib96","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/cpdd.1163","article-title":"Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients","volume":"11","author":"Hughes","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib97","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and Safety of the TYK2\/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.07.008_bib98","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1021\/acs.jmedchem.1c01137","article-title":"Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2\/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111238","article-title":"Therapeutic potential of a synthetic dual JAK1\/TYK2 inhibitor in inflammatory bowel disease","volume":"126","author":"Cui","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.07.008_bib100","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn\u2019s Disease: Prospective Real-World Experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib101","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn\u2019s Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib102","unstructured":"Reistone Biopharma Company Limited, A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease., \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT036776482024\u3009 2023 (Accessed 15 May 2024)."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.07.008_bib103","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib104","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izad300","article-title":"Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease","author":"Spencer","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10620-022-07582-w","article-title":"Upadacitinib Is Safe and Effective for Crohn\u2019s Disease: Real-World Data from a Tertiary Center","volume":"68","author":"Traboulsi","year":"2022","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.07.008_bib106","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111229","article-title":"Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies","volume":"126","author":"Zheng","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib108","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","article-title":"Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial","volume":"22","author":"Zhao","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"issue":"10066","key":"10.1016\/j.cytogfr.2024.07.008_bib109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cytogfr.2024.07.008_bib110","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ibd\/izab253","article-title":"Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes\/Pathways of Patients With Moderately to Severely Active Crohn\u2019s Disease","volume":"28","author":"Roblin","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib111","doi-asserted-by":"crossref","DOI":"10.2196\/42574","article-title":"Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study","volume":"12","author":"Plachta-Danielzik","year":"2023","journal-title":"JMIR Res. Protoc."},{"issue":"17","key":"10.1016\/j.cytogfr.2024.07.008_bib112","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"502","key":"10.1016\/j.cytogfr.2024.07.008_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.07.008_bib114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.07.008_bib115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/cts.12929","article-title":"Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study","volume":"14","author":"Singh","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.07.008_bib116","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a Dual JAK3\/TEC Family Kinase Inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.07.008_bib117","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib118","article-title":"Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis","author":"Hassan-Zahraee","year":"2023","journal-title":"J. Crohn'S. Colitis"},{"key":"10.1016\/j.cytogfr.2024.07.008_bib119","unstructured":"Pfizer, Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease., \u3008https:\/\/clinicaltrials.gov\/study\/NCT033951842024\u3009 2024 (Accessed 15 May 2024)."},{"issue":"37","key":"10.1016\/j.cytogfr.2024.07.008_bib120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035020","article-title":"Pathological mechanism and targeted drugs of ulcerative colitis: A review","volume":"102","author":"Guo","year":"2023","journal-title":"Medicine"},{"issue":"48","key":"10.1016\/j.cytogfr.2024.07.008_bib121","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.3748\/wjg.v27.i48.8201","article-title":"Palmitoylation in Crohn\u2019s disease: Current status and future directions","volume":"27","author":"Cheng","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"814","key":"10.1016\/j.cytogfr.2024.07.008_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.add2282","article-title":"STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice","volume":"16","author":"Jiang","year":"2023","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186231","article-title":"Sirtuin family in autoimmune diseases","volume":"14","author":"Tao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2024.07.008_bib124","first-page":"1","article-title":"Honokiol Ameliorates DSS-Induced Mouse Colitis by Inhibiting Inflammation and Oxidative Stress and Improving the Intestinal Barrier","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.07.008_bib125","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/ibd\/izad099","article-title":"SIRT3 Activator Honokiol Inhibits Th17 Cell Differentiation and Alleviates Colitis","volume":"29","author":"Chen","year":"2023","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610124000510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610124000510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T03:17:10Z","timestamp":1726111030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610124000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":125,"alternative-id":["S1359610124000510"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.07.008","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}